Top Markets
#1 Akedo Akedo +114.63%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.38%
#4 Cross Cross +37.46%
#5 Black Phoenix Black Phoenix +34.01%
#6 Velvet Velvet +33.97%
#7 OVERTAKE OVERTAKE +18.40%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.68%
#9 QANplatform QANplatform +14.56%
#10 Illuvium Illuvium +12.98%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Aravive, Inc. Aravive, Inc.

Aravive, Inc.

ARAV
Clasificación en acciones #38758
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston,... Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.
Precio por acción
$0.0401
Última sincronización: 2024-02-07
Capitalización bursátil
$818.60K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Aravive, Inc. (ARAV)

Categoría

Healthcare
Historial del precio de la acción de Aravive, Inc. (ARAV)
Precio más alto de cierre: $0.04 el 2024-02-01

Precio más bajo de cierre: $182.57 el 2014-03-01
Historial del precio de la acción de Aravive, Inc. desde 2014 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2024 -69.29%
2023 -90.99%
2022 -45.24%
2021 -56.56%
2020 -50.99%
2019 201.32%
2018 -67.24%
2017 -85.05%
2016 18.54%
2015 -39.99%
2014 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $507.30 29.98%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $845.59 29.61%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 7.13%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.25%
BE